London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Kashdog,
At least you recognise and acknowledge that you're deviating from your normal strategy and emotions are coming in to play - even if you're not quite sure which emotion!
Bermuda, yes, I did know….I was trying to emphasise the timelines for Scancell’s progress.
I appreciate your previous and as usual informative post.
To be clear, I am a “believer” I just sometimes question my investment strategy here. I could sell half my holding here at the current SP and recover my initial investment and be on a free carry as we bought in 2019. That would be my normal play!… but for some reason I cannot bring myself to do that and don’t know if it is belief, instinct, or just plain greed!…being a gambler, I suspect the latter…so hoping my luck holds!…:-D
Kashdog,
Just to add in answer to your SCIB1 comment - those are 2 completely different trials, but I think you might have known that:)
Sorry Kash, I answered on Moditope ie. In response to the specific topic you raised a question against and also clearly described for all to see in the subject line.
Apples & Pears. Cheerio.
Morning Kashdog,
I don't think anyone here could disagree that there has been an inordinate delay in getting Modi1 into the clinic. It has nothing to do with covid, but is down to technical problems in manufacturing the vaccine. More specifically in conjugating the peptides to the amplivant adjuvant. Frustrating, but this is cutting edge technology and I understand that chemical synthesis of hydrophobic peptides is extremely complex and challenging. Full credit to Scancell for overcoming these issues.
There has been plenty of independent verification of the potential of Moditope in the preclinical setting - every single peer reviewed research paper, the BioNTech agreement (BioNTech would not have signed before carrying out due diligence on the preclinical data package), The calibre of the CRUK Grand Challenge team which was built around developing a Modi3 - some really big international names in the field of oncology research. etc. etc.
Finally, in terms of the actual management of the trials - most of it is carried out by 3rd parties and there is plenty of independent monitoring and oversight including:- study investigators, the principal investigator, the Ethics Committee, the regulators (MHRA/EMA/FDA) and the CRO to name a few.
It's really is a shame that it's taken so long to get Moditope into the clinic but we are where we are and at least now Scancell are finally on the brink of finding out whether the best immune response Lindy Durrant has seen in her entire career can be replicated in humans. Time will tell!!
From an RNS issued 31st Jan 2011
“The trial, which commenced in June 2010, is designed to evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma and also to gather data on the effects of SCIB1 on tumour growth and cellular immune response.”
This trial was expanded on June 15th this year!!…..12 years on !!!
“Early safety and immunogenicity data expected to be available in H2 2022”
Not even half way Kash.
10 years and Modi-1 has just (June 13th) had FPD in a phase 1 Clinical trial and Modi-2 still at pre clinical.
If it is such a wonder drug that melts tumours in four days, why is it taking so long to enter and complete trials. Let’s not use Covid as an excuse, although I can accept it would of had some impact.
Has there been any independent verification of Moditope’s potential or are the trials the only way of knowing. I assume that the trials are completely and totally managed by Scancell without any third party monitoring.
Monday morning musing prompted by cc’s post maybe!!
Add to that it’s been two months since FPD on the ModiFY trial.
well said , Happy birthday to Moditope
Moditope is 10 years old today.
On August 15th 2012,
Moditope was introduced to the world in the form of an RNS.
Richard Goodfellow, back then, said Moditope was a serendipity discovery and when Lindy sent him the email about it, he photocopied it, framed it and hung it on his office wall.
More recently Lindy Durrant said 'There has been a dramatic regression of large tumours in preclinical models. One injection and the tumour melts away within 4 days'
Let's hope that Lindy and Richard are right and Moditope with the other Scancell platforms are successful, not just for the long term holders on this bb, but also for the patients suffering around the world.